Entrada Therapeutics, Inc.
TRDA
$11.88
-$0.71-5.64%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 11.26% | -2.39% | -148.45% | -1,633.95% | 108.06% |
| Total Depreciation and Amortization | -27.97% | 18.96% | 9.30% | -4.64% | 5.87% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -14.90% | 7.10% | 9.02% | 70.95% | 33.15% |
| Change in Net Operating Assets | -76.99% | 20.26% | 132.85% | 28.03% | -180.24% |
| Cash from Operations | -13.74% | 3.99% | 23.42% | -21.84% | -30.24% |
| Capital Expenditure | 21.05% | 162.18% | 75.96% | -80.16% | 0.63% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -40.92% | 43.63% | 474.86% | -89.02% | 165.62% |
| Cash from Investing | -40.71% | 45.31% | 606.61% | -91.04% | 164.35% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 2,300.00% | -97.63% | -3.71% | -75.04% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 2,300.00% | -97.63% | -3.71% | -75.04% | 12,845.45% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -113.90% | 347.88% | 113.92% | -244.09% | 121.61% |